NDUFC1 Antibody

What is NDUFC1 and what is its biological function?

NDUFC1 (NADH: ubiquinone oxidoreductase subunit C1, also known as CI-KFYI) is an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I). Unlike core subunits, NDUFC1 is not directly involved in catalysis but plays a supportive function in stabilizing the complex structure. Complex I functions in the transfer of electrons from NADH to the respiratory chain, with ubiquinone being the immediate electron acceptor for the enzyme .

The protein works alongside other accessory proteins such as NDUFA1 and NDUFB5 within the complex to ensure proper electron flow from NADH to ubiquinone, which is essential for oxidative phosphorylation . Recent research has shown that NDUFC1 may have roles beyond its structural function in mitochondria, particularly in cancer progression and cell proliferation .

What applications are NDUFC1 antibodies suitable for?

Based on validated research protocols, NDUFC1 antibodies have been successfully used in the following applications:

When designing experiments, researchers should perform optimization for their specific tissue or cell type, as optimal dilutions may vary between experimental systems .

How should NDUFC1 antibodies be stored and handled?

For optimal antibody performance and longevity, follow these research-validated storage conditions:

• Store at -20°C in aliquots to minimize freeze-thaw cycles

• Use buffers containing 0.02% sodium azide and 50% glycerol at pH 7.3

• Antibody remains stable for approximately one year after shipment when properly stored

• For concentrated formulations (typically 20μl sizes), note that they may contain 0.1% BSA

Researchers should avoid repeated freeze-thaw cycles as this can lead to protein denaturation and reduced antibody performance. For working solutions, store at 4°C for short-term use (up to one week).

What positive controls should be used when working with NDUFC1 antibodies?

Based on published research, the following tissues and cell lines have been validated as positive controls for NDUFC1 expression:

Human Tissues:

• Human kidney tissue

• Human heart tissue

Cell Lines:

• MGC-803 (gastric cancer cell line)

• SGC-7901 (gastric cancer cell line)

• BEL-7404 (hepatocellular carcinoma cell line)

• SK-HEP-1 (liver adenocarcinoma cell line)

• U-2 OS (osteosarcoma cell line)

When establishing control parameters, researchers should consider that NDUFC1's expression may vary significantly between normal and cancerous tissues, which can serve as internal controls in comparative studies .

How does NDUFC1 expression correlate with cancer progression and clinical outcomes?

NDUFC1 has emerged as a potential biomarker and therapeutic target in multiple cancer types. Studies have revealed significant correlations between NDUFC1 expression and clinical parameters:

In Gastric Cancer:

• Overexpressed NDUFC1 correlates with more serious tumor infiltrates

• Higher risk of lymphatic metastasis

• Higher proportion of positive lymph nodes

• More advanced tumor stage

In Hepatocellular Carcinoma (HCC):

Statistical analyses using Chi-squared tests and Spearman's rank correlation coefficient analysis have confirmed the relationship between NDUFC1 expression and tumor characteristics in patients with gastric cancer (p < 0.05) . Additionally, analysis of the GEO database (GSE49051) demonstrated elevated NDUFC1 in gastric cancer tissues compared to non-tumor tissues .

What signaling pathways are affected by NDUFC1 modulation in cancer cells?

NDUFC1 appears to influence several key oncogenic signaling pathways, with the PI3K/Akt/mTOR pathway being particularly significant:

PI3K/Akt/mTOR Pathway:

• NDUFC1 knockdown decreases phosphorylation levels of Akt and mTOR

• Reduced expression of downstream targets including CCND1, CDK6, and PIK3CA

• Decreased anti-apoptotic proteins (Bcl-2, Survivin, XIAP)

Rescue Experiments:

• PI3K/AKT signaling pathway agonist SC79 rescues the inhibitory effects on cell proliferation and migration

• SC79 treatment reverses the pro-apoptotic effects caused by NDUFC1 knockdown

• SC79 administration restores expression of P-Akt, Bcl-2, Survivin, and XIAP in NDUFC1-knockdown cells

Additional Pathways:

• p53 pathway interaction suggested in HCC studies

• Potential involvement in regulating autophagy and cellular senescence

• Impact on mitochondrial Complex I activity and ROS levels

These findings suggest that NDUFC1 may exert its oncogenic effects primarily through activation of the PI3K/Akt/mTOR pathway, offering potential avenues for therapeutic intervention.

How does NDUFC1 affect mitochondrial function and oxidative stress in cancer cells?

Research has demonstrated that NDUFC1 modulation significantly impacts mitochondrial function and oxidative stress parameters:

Effects on Complex I:

Reactive Oxygen Species (ROS):

• NDUFC1 knockdown increases intracellular ROS levels

• Potential mechanism for observed effects on cell proliferation and apoptosis

• May contribute to cellular senescence induction

Experimental Approaches:
When studying NDUFC1's role in mitochondrial function, researchers have successfully employed:

• Complex I activity assays to directly measure enzyme function

• ROS detection methods (e.g., fluorescent probes)

• Analysis of senescence-related genes through bioinformatics approaches

These findings suggest a paradoxical relationship where NDUFC1, despite being part of the respiratory chain, may promote cancer progression through mechanisms that involve altered mitochondrial function and ROS regulation.

What technical challenges exist in NDUFC1 antibody-based research and how can they be addressed?

Researchers working with NDUFC1 antibodies face several technical challenges that require methodological considerations:

Antibody Specificity:

• NDUFC1's small size (76 aa, 9 kDa) may present challenges for antibody specificity

• Validation through knockout/knockdown controls is essential

• Western blot analysis should confirm the expected molecular weight

Signal Optimization in IHC:

• Antigen retrieval is critical; TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 can serve as an alternative

• Signal development time requires optimization; DAB color development for approximately 10 minutes has been reported

• Counterstaining with hematoxylin provides contrast for accurate assessment

Quantification Methods:
For immunohistochemistry, standardized scoring systems have been employed:

• Staining percentage scores: 1 (1–24%), 2 (25–49%), 3 (50–74%), and 4 (75–100%)

• Staining intensity scores: 0 (signalless), 1 (brown), 2 (light yellow), and 3 (dark brown)

• Final IHC score determined by combining percentage and intensity scores

Statistical Analysis:

• For tissue comparisons, sign tests have been used to analyze differences in NDUFC1 levels

• Two-group comparisons conducted using two-tailed Student's t-test

• Multiple comparisons carried out by one-way ANOVA with post hoc Student–Newman–Keuls test

How can NDUFC1 be targeted for potential therapeutic interventions?

Based on current research, several approaches for targeting NDUFC1 show therapeutic potential:

RNA Interference:

• shRNA-mediated silencing has demonstrated efficacy in preclinical models

• Significant inhibition of tumor growth observed in xenograft models

Pathway Inhibition:

• Combined targeting of NDUFC1 and PI3K/Akt pathway may enhance therapeutic effects

• Potential for synergistic effects with existing PI3K/Akt inhibitors

Mitochondrial Metabolism Therapy:

• NDUFC1 represents a novel target for mitochondrial metabolism-based cancer therapies

• May have particular relevance in cancers with altered metabolic profiles

Biomarker Potential:

• NDUFC1 expression could serve as a prognostic biomarker

• May help identify patients who would benefit from mitochondrial-targeted therapies

Current evidence suggests that targeting NDUFC1 could open innovative perspectives for new multi-targeting approaches in cancer treatment, particularly in gastric cancer and hepatocellular carcinoma where its role has been most thoroughly investigated .